Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 4/20 | 0.41 |
| ▸ | HTR2B | P41595 | 4/20 | 0.41 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | AHCY | P23526 | 1/20 | 0.34 |
| ▸ | SLC29A1 | Q99808 | 5/20 | 0.34 |
| ▸ | ADA | P00813 | 1/20 | 0.33 |
| ▸ | PGK1 | P00558 | 1/20 | 0.33 |
| ▸ | PGK2 | P07205 | 1/20 | 0.33 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19777952 | 0.92 | ADORA2A (0.36) | HTR2CHTR2BTMIGD3CYP2C19ADORA2A | |
| SCHEMBL19778108 | 0.90 | CCNE2 (0.37) | HTR2CHTR2BTMIGD3CYP2C19ADORA2A | |
| SCHEMBL19778494 | 0.90 | CCNE2 (0.37) | HTR2CHTR2BTMIGD3CYP2C19ADORA2A | |
| SCHEMBL21015893 | 0.89 | HTR2C (0.41) | HTR2CHTR2BTMIGD3ADORA2AADORA3 | |
| SCHEMBL19778484 | 0.89 | HTR2C (0.41) | HTR2CHTR2BTMIGD3ADORA2AADORA3 | |
| SCHEMBL19859703 | 0.88 | ADORA2A (0.46) | CYP2C19ADORA2AADORA3ADORA1AHCY | |
| SCHEMBL21015896 | 0.85 | P2RY1 (0.41) | ADORA3 | |
| SCHEMBL21015191 | 0.84 | ADORA3 (0.53) | HTR2CHTR2BADORA2AADORA3ADORA1 | |
| SCHEMBL16647595 | 0.83 | ADORA2A (0.39) | CYP2C19ADORA2AADORA3ADORA1AHCY | |
| SCHEMBL21015897 | 0.83 | P2RY1 (0.43) | ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10711029-B2 | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection | Atea Pharmaceuticals, Inc. (US) | 2020-07-14 | — | — | US | disclosed |
| US-10711029-B2 | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection | Atea Pharmaceuticals, Inc. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190153017-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-4'-FLUORO-N6-SUBSTITUTED-6-AMINO-2-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION | Atea Pharmaceuticals, Inc. (US) | 2019-05-23 | — | — | US | disclosed |
| US-20190153017-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-4'-FLUORO-N6-SUBSTITUTED-6-AMINO-2-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION | Atea Pharmaceuticals, Inc. (US) | 2019-05-23 | — | — | US | disclosed |
| WO-2018013937-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-4'-FLUORO-N6-SUBSTITUTED-6-AMINO-2-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION | Atea Pharmaceuticals, Inc. (US) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190153017-A1 | BETA-D-2'-DEOXY-2'-ALPHA-FLUORO-2'-BETA-C-SUBSTITUTED-4'-FLUORO-N6-SUBSTITUTED-6-AMINO-2-SUBSTITUTED PURINE NUCLEOTIDES FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTION | PNP, SLC29A2, NT5C2 | HTR2C 1522/4885HTR2B 2105/4885TMIGD3 4380/4885 |
| US-10711029-B2 | Beta-d-2′-deoxy-2′-alpha-fluoro-2′-beta-c-substituted-4′fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection | PNP, SLC29A2, NT5C2 | HTR2C 1604/4885HTR2B 2248/4885TMIGD3 4300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.